ArticleAlimentary pharmacology & therapeutics2017
The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.
Article in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Prevalence of Comorbidities in Inflammatory Bowel Disease: An Umbrella Review of 18 Systematic Reviews.Journal of clinical medicine · 2026Review
- Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition.BMC medicine · 2025Review
- Coexisting autoimmune disorders among patients with inflammatory bowel disease at a tertiary center in Saudi Arabia: A cross-sectional study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Gut microbial and human genetic signatures of inflammatory bowel disease increase risk of comorbid mental disorders.NPJ genomic medicine · 2024Article
- Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases.Digestive diseases and sciences · 2024Article
- Prevalence of stricturing, penetrating complications and extraintestinal manifestations in inflammatory bowel disease detected on cross-sectional imaging in a tertiary care setting.United European gastroenterology journal · 2024Article
- Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey.Journal of clinical medicine · 2024Article
- Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study.Journal of clinical medicine · 2024Article
- Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project.Clinical epidemiology · 2024Article
- Contrasting Autoimmune Comorbidities in Microscopic Colitis and Inflammatory Bowel Diseases.Life (Basel, Switzerland) · 2023Article
- Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden.Journal of Crohn's & colitis · 2022Article
- Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases.World journal of gastroenterology · 2022Review
- Article
- Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.Therapeutic advances in gastroenterology · 2022Review
- Overrepresentation of Enterobacteriaceae andFrontiers in cellular and infection microbiology · 2022Article
- Review
- Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis.Inflammatory bowel diseases · 2021Article
- Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.Therapeutic advances in gastroenterology · 2021Article
- Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review.Advances in therapy · 2020Review
- Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach.Scientific reports · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInflammatory bowel diseases lead to progressive bowel damage and need for surgery. While the increase in prevalence of other immune-mediated diseases in IBD is well recognised, the impact of this on the natural history of IBD is unknown.
aimTo determine the impact of concomitant immune-mediated diseases on phenotypes and outcomes in IBD.
methodsPatients with IBD enrolled in a prospective registry were queried about the presence of other immune-mediated diseases, defined as those where immune dysregulation plays a role in pathogenesis. Demographics and disease-related information were obtained. Subjects also completed measures of quality of life. Multivariable regression models compared disease phenotype and outcomes of IBD patients with and without other immune-mediated diseases.
resultsThe cohort included 2145 IBD patients among whom 458 (21%) had another immune-mediated disease. There was no difference in CD phenotype between the two groups. UC patients were more likely to have pancolitis in the presence of another immune-mediated disease (62%) compared to those without (52%, P = 0.02). IBD patients with another immune-mediated disease had higher rates of needing anti-TNF biologics [Odds ratio (OR) 1.31, 95% CI 1.05-1.63] and surgery (OR 1.26, 95% CI 0.99-1.61). The presence of another immune-mediated disease was also associated with lower disease-specific and general physical quality of life.
conclusionsThe presence of another immune-mediated disease in IBD patients was associated with higher likelihood of pancolonic involvement in UC, and a modest increase in need for IBD-related surgery and anti-TNF biological therapy. Such patients also experienced worse quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.